A Single Center, Open-label Study to Evaluate the Effects of a Single 1200mg IV Dose of Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers

Trial Profile

A Single Center, Open-label Study to Evaluate the Effects of a Single 1200mg IV Dose of Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Anthrax; Bacteraemia; Clostridium infections; Gram-positive infections; Skin and soft tissue infections
  • Focus Pharmacodynamics
  • Sponsors The Medicines Company
  • Most Recent Events

    • 12 Dec 2016 Results published in the Antimicrobial Agents and Chemotherapy.
    • 30 Oct 2016 Results assessing interference of Oritavancin on coagulation tests presented at the IDWeek 2016.
    • 16 Mar 2015 Status changed from recruiting to completed as per ClinicalTrials.gov reocrd.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top